New Service Offerings from SleepScore Labs Leverage 65 Million Hours of Holistic Sleep Data to Help Leading Companies Improve Sleep for Millions by Connecting the Dots

The Sleep Science Company Announces End-to-End Suite of Tools and Services to Help Companies Stand Apart & Deliver Science-Backed Innovation Amidst a Crowded Sleep Industry SleepScore Labs[1], the Sleep Science Company behind the world’s most comprehensive suite of data-backed sleep solutions, today announced a suite of new tools and services supporting partners in the sleep space. Harnessing their 65 million...

READ MORE New Service Offerings from SleepScore Labs Leverage 65 Million Hours of Holistic Sleep Data to Help Leading Companies Improve Sleep for Millions by Connecting the Dots

Custom nanoparticle regresses tumors when exposed to light (Penn State)

(Penn State) UNIVERSITY PARK, Pa. — A unique nanoparticle to deliver a localized cancer treatment inhibits tumor growth in mice, according to a team of Penn State This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are...

READ MORE Custom nanoparticle regresses tumors when exposed to light (Penn State)

Intensity Therapeutics Announces Publication of Research Reporting that Intratumoral Administration of INT230-6 Demonstrates Tissue Dispersive Properties, Tumor Regression and Elicits Systemic Adaptive Immunity

Intensity Therapeutics announces publication of research showing that administration of INT230-6 demonstrates tumor regression and an immune response. June 25, 2020 07:36 AM Eastern Daylight Time WESTPORT, Conn.–( BUSINESS WIRE )– Intensity Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a novel, immune-based drug approach to treat solid tumor cancers through direct tumor injection, today announced the publication of results...

READ MORE Intensity Therapeutics Announces Publication of Research Reporting that Intratumoral Administration of INT230-6 Demonstrates Tissue Dispersive Properties, Tumor Regression and Elicits Systemic Adaptive Immunity